Manipulation of Regulatory Dendritic Cells for Induction Transplantation Tolerance

Weitao Que1,2, Wen-Zhi Guo1 and Xiao-Kang Li1,2*

1 Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, 2 Division of Transplantation Immunology, National Research Institute for Child Health and Development, Tokyo, Japan

Current organ transplantation therapy is life-saving but accompanied by well-recognized side effects due to post-transplantation systemic immunosuppressive treatment. Dendritic cells (DCs) are central instigators and regulators of transplantation immunity and are responsible for balancing allograft rejection and tolerance. They are derived from monocyte-macrophage DC progenitors originating in the bone marrow and are classified into different subsets based on their developmental, phenotypical, and functional criteria. Functionally, DCs instigate allograft immunity by presenting donor antigens to alloreactive T cells via direct, indirect, and semidirect recognition pathways and provide essential signaling for alloreactive T cell activation via costimulatory molecules and pro-inflammatory cytokines. Regulatory DCs (DCregs) are characterized by a relatively low expression of major histocompatibility complex, costimulatory molecules, and altered cytokine production and exert their regulatory function through T cell anergy, T cell deletion, and regulatory T cell induction. In rodent transplantation studies, DCreg-based therapy, by in situ targeting or infusion of ex vivo generated DCregs, exhibits promising potential as a natural, well-tolerated, organ-specific therapeutic strategy for promoting lasting organ-specific transplantation tolerance. Recent early-phase studies of DCregs have begun to examine the safety and efficacy of DCreg-induced allograft tolerance in living-donor renal or liver transplantations. The present review summarizes the basic characteristics, function, and translation of DCregs in transplantation tolerance induction.

Keywords: allograft, dendritic cell, T cell, tolerance, transplantation

INTRODUCTION

Organ transplantation has progressed greatly over the past half-century to become the optimal treatment for a variety of end-stage organ diseases. However, the life-long, systemic immune suppression after a transplantation has major associated adverse effects, including severe infections, malignancies, psychosocial issues affecting patients, and a high cost to the health care system (1, 2). Immunosuppressive drugs can prevent acute cellular rejection but fail to control donor-specific antibody production and later-phase chronic organ rejection that may eventually lead to graft failure (3–5). Donor-specific tolerance is recognized as superior to systemic immunosuppression in being more conducive to donor organ acceptance without compromising host protective immunity. In this context, regulatory immune cell-based therapies are emerging as novel, promising strategies for establishing permanent donor-specific immune tolerance and minimizing or even obviating...
the need for immunosuppressive drugs after organ transplantation. Many types of regulatory immune cells, such as regulatory T cells (Tregs) (6), type 1 regulatory T cells (Tr1) (7), regulatory macrophages, regulatory B cells (Bregs) (5, 8), myeloid-derived suppressor cells (9), and regulatory dendritic cells (DCregs) (10), have already been investigated in animal transplantation models, and entered the clinical trials in organ transplantation and shown clear benefits in terms of safety and graft survival (11, 12). Among these cells, DCregs are particularly attractive due to their role as central regulators of the immune response.

**BASIC PROFILE OF DCs**

DCs are a rare, heterogeneous population of the most efficient antigen-presenting cells (APCs) derived from bone marrow. They play a critical role in the instigation and regulation of the immune response (13, 14). DCs are distributed ubiquitously throughout the body and serve as immunologic sentinels specialized in sensing danger signals and capturing, processing, and presenting antigenic materials (13, 15–17). DCs can initiate both the innate and adaptive immune responses, for example, via natural killer (NK) cells and cytotoxic T cells. In these processes, DCs undergo complicated phenotypical and functional changes in response to the environment, signals, and antigens (18).

Based on their developmental, phenotypical, and functional features, DCs can be categorized into several different subsets. Traditionally, DCs were subdivided into classical or conventional DCs (cDCs), plasmacytoid DCs (pDCs), monocyte-derived DCs (MoDCs), and langerhans cells (LCs) (19). All subsets of DCs express major histocompatibility complex (MHC) class II and CD11c surface molecular markers. The cDC subtype regularly located in lymphoid organs and most non-lymphoid organs has a superior ability to capture, process, and present antigens to naïve T cells. Indeed, studies of transgenic mice, constitutive or conditionally deficient in cDCs, have confirmed the central role of cDCs in priming the naïve T cell response (20, 21). The cDC subtypes can be further subdivided into cDC1 (CD8α+CD103+ in mice; CD141+ in humans) and cDC2 (CD11b+ in mice; CD1c+ in human) subsets. Moreover, the cDC1 subset is adept in cross-presentation and priming CD8+ cytotoxic T cells while the cDC2 subset is most proficient at driving the CD4+ T cell response (22–24). The pDCs patrolling the blood and peripheral organs excel in producing high levels of type I IFN in response to viruses and RNA/DNA or immune complexes, a direct consequence of their constitutively expressing IRF7 (25, 26). They also participate in antigen presentation, control the T cell response, and usually exhibit tolerogenic properties by favoring the generation of Tregs (27, 28). MoDCs, also known as inflammatory DCs, derive from monocytes infiltrating under inflammatory conditions and are capable of releasing large amounts of tumor necrosis factor alpha (TNF-α) and inducible nitric oxide synthase (iNOS) upon pathogen recognition (29). Although identified as a subset of DCs, MoDCs share many features with both cDCs and macrophages, and their classification is still debated (30, 31). LCs are a distinct subset of DCs resident in the epidermal layer of the skin. Although LCs are similar to cDCs in terms of phenotype and function, they also have unique differentiation and homeostatic features (19, 32). LCs are generated from embryonic hematopoietic precursors which are seeded in the skin in the prenatal period and self-renew in situ at a very low rate under physiological steady-state conditions without replenishment by blood-borne precursors (33, 34). In contrast to cDCs, LC development is independent of FMS-like tyrosine kinase 3 (Flt3) and Flt3 ligand (Flt3L) but requires colony-stimulating factor 1 receptor (Csf-1R) like many tissue-resident macrophages, such as microglial cells and Kupffer cells (35, 36). Recently, IL-34 has been identified as the second functional ligand for Csf-1R and was required for the development of LCs and microglial cells (37). In the current classification of DCs, it is unclear whether DCregs constitute an independent DC subset or represent a specific functional state of DCs. In fact, most DC subsets can exert regulatory function through T cell anergy, T cell deletion, and Treg induction (38, 39).

The lifespan of DCs is generally short, and continuous replenishment from bone marrow progenitors is essential to maintaining DC homeostasis (40). Except for LCs, the majority of DC subsets originate from the same progenitors, namely monocyte-macrophage DC progenitors (MDPs), which reside in the bone marrow (19, 41) (Figure 1). MDPs further give rise to common monocyte progenitors (cMoPs) and common DC progenitors (CDPs) (42, 43). cMoPs develop into blood monocytes in the bone marrow but further differentiate into MoDCs in tissue as a consequence of inflammation or infection (29, 43–46). CDPs further give rise to pDCs and pre-DCs (47, 48). pDCs terminally differentiate into fully developed cells in the bone marrow, then migrate out to patrol the blood and peripheral organs (49, 50). Pre-DCs migrate out of the bone marrow through the blood to seed non-lymphoid and lymphoid organs, where they terminally differentiate into cDCs (36, 51, 52). LCs derive predominantly from embryonic fetal liver monocytes with a minor contribution from yolk sac-derived macrophages and are maintained locally by self-renewal under steady-state conditions (33, 53). In severe inflammatory conditions, LCs are replaced by blood-borne monocytes and acquire the capacity for self-renewal (35, 54).

**FUNCTION OF DCs IN TRANSPLANTATION**

DCs are critical to linking the innate and adaptive response in transplantation, in other words, to initiating robust, donor-specific, alloreactive T cell activation. During a classical immune response, immature DCs sense the presence of damage- and pathogen-associated molecular patterns (DAMPs and PAMPs), the so-called "Signal 0s," from damaged cells and microbial molecules, respectively, via pattern recognition receptors (PRRs) (55, 56). These PRRs mediate internalized antigens and their routing to antigen-processing pathways (57). Subsequently, PRRs activate a series of intracellular pro-inflammatory molecular signaling cascades, such as interferon-responsive factor and nuclear factor kappa B pathways (58, 59). Activation of these signaling pathways leads to maturation of DCs, characterized as the "Signal 1s."
Figure 1 | Origin and development of dendritic cells. With the exception of LCs, DCs develop from bone marrow-derived precursors. CDPs give rise to cDCs and pDCs. Monocytes differentiate into MoDCs in tissue as a consequence of inflammation or infection. LCs originate in prenatal precursor cells and are maintained locally by self-renewal under steady-state conditions. While under a severe inflammatory condition, LCs are replaced by blood-borne monocytes and acquire the capacity of self-renewal. DC, dendritic cell; LC, langerhans cells; CDP, common dendritic cell progenitor; cDC, classical dendritic cell; pDC, plasmacytoid dendritic cell; MoDC, monocyte-derived dendritic cell; YS-EMPs, Yolk sac-derived erythromyeloid progenitor cells; P-Sp/AGM para-aortic splanchnopleure/aorta, gonads, and mesonephros; HSC, hematopoietic stem cells; CMP, common myeloid progenitor cell; MP, myeloid progenitor cell; cMoP, common monocyte progenitor; GMP, granulocyte-macrophage progenitor; MDP, monocyte-macrophage DC progenitor.

by upregulation of MHC molecules, costimulatory molecules (e.g., CD80, CD86), chemokine receptors (e.g., C-C chemokine receptor type 7, CCR7), adhesion molecules (e.g., CD62L), and pro-inflammatory cytokines (e.g., TNF-α, IL-12) (60–62). Chemokine receptors and adhesion molecules permit DCs to migrate to lymphoid organs, where they contact and prime T
cells (63–65). Antigens loaded on MHC class I molecules are presented to CD8+ T cells, whereas antigens loaded on MHC class II molecules are presented to CD4+ T cells. Costimulatory molecules and pro-inflammatory cytokines provide the essential signals for T cell activation (66, 67).

Unlike immune responses to conventional antigens, the trigger of allograft immunity relies on both donor- and host-derived DC-mediated antigen recognition (Figure 2). Following transplantation, donor-derived DCs migrate out of the graft to the graft-draining lymphoid tissues, where they directly present intact, donor (alloimmune) MHC molecules to alloreactive T cells. The direct allore cognition pathway is considered to dominate primary immune responses following allografting, which leads to acute graft rejection. The donor-derived DCs are rapidly eliminated by the early response of NK cells. Thus, direct allore cognition decreases along with a drop in the number of donor-derived DCs after transplantation. Meanwhile, host-derived DCs capture, process, and present donor-derived antigens to alloreactive T cells via the indirect pathway. These donor-derived antigens originate in damaged donor cells within a graft or in dying donor-derived DCs within draining secondary lymphoid organs. The indirect allore cognition pathway partially contributes to the early alloreponses and gradually dominates, leading to alloantibody production and chronic rejection. In addition, alloreactive T cells can also be stimulated via the semidirect allore cognition pathway, i.e., the recognition of intact donor MHC molecules transferred to host DCs by cell-cell contact or extracellular vesicles. The semidirect allore cognition pathway generates effector T cells that are donor MHC-restricted, as with the direct allore cognition pathway. Although each of these allore cognition pathways can solely or synergistically lead to allograft rejection, the maturity of DCs greatly influences the magnitude and quality of the T cell response (68–70).

T cells are critical players in transplantation immunity, which directly mediates allograft rejection. The activation of alloreactive T cells depends on three distinct DC-derived signals, including T-cell receptor engagement (signal 1), costimulation (signal 2), and cytokine stimulation (signal 3) (66). These DC-derived signals determine the fate of alloreactive T cells and tilt the balance toward graft survival or rejection (71). DCregs comprise a heterogeneous population of immature or semi-mature DCs characterized by a relatively low expression of MHC class II molecules, costimulatory molecules, and altered cytokine production. DCregs are thought to exert their regulatory function through various mechanisms (Figure 3). With the presentation of low levels of antigens in the absence of costimulatory molecules, such as CD80 and CD86, T cells will become anergic and lose their ability to proliferate (72, 73).

The presence of coinhibitory signals during T cell activation, such as programmed cell death 1 (PD-1) and PD ligand 1 (PD-L1) interaction, CD80/CD86 and cytotoxic T lymphocyte antigen 4 (CTLA-4) interaction, inducible T-cell costimulator (ICOS) and ICOS ligand (ICOS-L) interaction, and heme oxygenase-1 (HO-1), can also lead to T cell anergy (74–78). HO-1 expression was also shown to be beneficial to DC survival and immunoregulatory properties (79, 80). Altered cytokine production; low levels of pro-inflammatory cytokines, such as IL-12; and high levels of anti-inflammatory cytokines, such as transforming growth factor β (TGF-β) and IL-10 mediate T cell anergy and Treg induction (81). DCregs can also induce clonal deletion of alloreactive T cells via the Fas/Fasl pathway or indoleamine 2,3-dioxygenase (IDO)-induced apoptosis (82, 83). Furthermore, DCregs can induce several subtypes of regulatory lymphocytes, including classical Foxp3+ Tregs, Tr1, CD8+ Tregs, and Bregs via mechanisms involving direct cell-cell interaction signaling through surface molecules (e.g., immunoglobulin-like transcript (ILT)-3/4, CTLA-4, PD-L1, FasL, ICOS-L, and others), as well as the immunosuppressive milieu through secretory factors (e.g., IL-10, TGF-β, IL-27, IL-35, IDO, retinoic acid, adenosine, HO-1, and nitric oxide). DCregs and Tregs interact with each other through a self-maintaining regulatory loop required for maintaining immune tolerance (84).

**EX VIVO GENERATED DCregs**

DCreg induction has been intensively studied for its potential therapeutic value in transplantation (Figure 4). The current literature has described various protocols for generating DCregs *ex vivo*. Generally, DCregs are generated from bone marrow precursors in rodents and from CD34+ hematopoietic precursors or blood monocytes (CD14+) in humans (85). The most widely used strategy is the deployment of culture progenitors using granulocyte-macrophage colony-stimulating factor (GM-CSF) ± IL-4 with the addition of one or more pharmacological agents that stably inhibit their maturation and promote their tolerogenicity (86, 87). GM-CSF is a critical cytokine required for *ex vivo* DC generation, but some researchers have used Flt3L instead of GM-CSF for DCreg differentiation (88, 89). The pharmacological agents include IL-10, dexamethasone, vitamin D3, rapamycin, and others (87, 90, 91). DCregs conditioned by IL-10 are resistant to maturation and are capable of inducing antigen-specific T cell anergy and Treg activity (92–94). IL-10-modulated DCs are the most suitable candidate for DC-based transplantation tolerance induction therapy (95). IL-10-induced monocyte-derived DCregs, characterized by a high IL-10/IL-12 ratio and high expression levels of tolerogenic molecules, HLA-G and ILT-4, are potent inducers of adaptive Tr1 cells (96). Dexamethasone-induced DCregs express low levels of costimulatory molecules but high levels of inhibitory receptors, ILT-2 and ILT-3, and produce high amounts of IL-10 and IDO (95, 97, 98). Vitamin D3 and its analogs promote the tolerogenic phenotype of DCreg via the induction of effector T apoptosis and generation of antigen-specific Tregs (90, 99, 100). The combined use of dexamethasone and vitamin D3 leads to “alternatively activated” DCs with an enhanced migration ability inducing memory T cell hyporesponsiveness while skewing naive T cells toward a low IFN-γ/high IL-10 cytokine profile (101, 102). Rapamycin-conditioned DCs have attracted much attention for their role in alloantigen Foxp3+ Treg expansion and migratory activity via enhancing CCR7 expression (91, 103).

Although pharmacological conditioning offers effective strategies for *ex vivo* generation of DCregs, there are some
limitations in \textit{ex vivo}-generated DCregs, such as undesirable pro-inflammatory factors, rematuration \textit{in vivo}, and low migratory activity. Genetic manipulation by adenovirus vectors and small interfering RNAs (siRNAs) provides a powerful tool for modifying specific features of \textit{ex vivo}-generated DCregs (104). Previous studies have reported that gene silencing of CD80/CD86 and IL-12 promoted the regulatory activity of DCregs (105, 106). Genetic interference with NF-κB induced a stable immature state by preventing the rematuration of DCregs (107). Dong et al. reported that concurrent CCR7 overexpression and RelB knockdown in DCregs displayed enhanced migratory and regulatory activity (108).

In addition to DCregs generated naturally from progenitor cells, we generated DCregs from murine induced pluripotent stem cells (iPSCs), which were able to remain in a stable immature state even under strong stimulation (109). iPSC-derived DCregs worked as a therapeutic cellular vaccine to generate Tregs and induced donor-specific allograft acceptance. Other researchers have explored using human PSCs, including iPSCs and embryonic stem cells, as a source of DCs for immune therapy (110–112). These studies have highlighted the potential of PSC-derived DCregs in clinical transplantation.

As discussed above, transplantation immunity involves both donor- and host-derived DCs via three allorecognition pathways. Therefore, there is a question of whether DCregs should be derived from the donor or the host. It is also worth noting that the risk of host-sensitization to donor antigens due to the presence of transferred allogeneic molecules should be taken into consideration in DCreg-based therapy. The therapeutic efficacy of DCregs in organ transplantation was first examined by Rastellini et al. and Fu et al. (113, 114). Donor-derived DCregs, infused 1 week before transplantation, significantly prolonged the survival of murine non-vascularized (pancreatic islet) and vascularized (heart) allografts. Alloantigen-specific T-cell anergy was observed \textit{in vitro}. Subsequently, the role of DCreg-based therapy was explored extensively in multiple transplantation models and clinical studies (10). The sources of the DCregs included donor-derived DCregs and host-derived DCregs, either pulsed or unpulsed with donor antigens. Additional host treatment, including costimulation blockade, conventional immunosuppressive drugs, and lymphocyte depletion, was used.

\textbf{FIGURE 2} \textbf{| Allorecognition pathways in transplantation.} DCs instigate allograft immunity by presenting donor antigens to alloreactive T cells via direct, indirect, and semidirect recognition pathways. In the direct pathway, donor-derived DCs directly present intact donor (allogeneic) MHC molecules to alloreactive T cells. In the indirect pathway, host-derived DCs present donor-derived antigens, captured from damaged graft tissue or dying, donor-derived DCs, to alloreactive T cells. In the semidirect pathway, intact donor MHC molecules transferred to host DCs by cell-cell contact or extracellular vesicles are recognized. DC, dendritic cell; MHC, major histocompatibility complex; TCR, T-cell receptor.
as an alternative combination to enhance tolerogenic properties and to minimize the risk of host sensitization. These studies have extensively investigated the safety and efficiency of donor- and host-derived DCregs. Although donor-derived DCregs were shown to be capable of inducing transplant tolerance in vivo, the underlying mechanisms remain unclear. It is generally assumed that donor-derived DCregs mediate transplantation tolerance via the direct allorecognition pathway, leading to alloreactive T cell anergy, T cell deletion, or Treg induction. However, Divito et al. demonstrated that host DCs mediated the therapeutic effects of the infused donor-derived DCregs (115), which are likely to be rapidly killed by host NK cells or captured and reprocessed by host splenic DCs, which induce Tregs and graft tolerance. This notion was further supported by the finding that the depletion of host DCs abrogates the tolerogenic effects of donor-derived DCregs (116).
FIGURE 4 | Manipulation of regulatory dendritic cells to promote transplantation tolerance. DCreg-based therapy is a promising strategy for establishing permanent, donor-specific immune tolerance and minimizing or even obviating the use of immunosuppressive drugs in transplantation. Manipulation of DCregs can be done by in situ targeting or infusion of ex vivo-generated DCregs or mediating donor-specific tolerance via alloreactive T cell anergy, T cell deletion, and Treg induction.
Contrary to the accepted paradigm, donor-derived DCregs function as antigen-transporting cells rather than APCs to promote transplantation tolerance. Alternatively, host-derived DCregs, either pulsed or unpulsed with donor antigens, have also been used to regulate the alloreactive T cell response and promote transplantation tolerance (117, 118). Taner et al. showed that infusion with rapamycin-treated, alloantigen-pulsed, host-derived DCregs 1 week before transplantation induced antigen-specific T cell regulation and prolonged graft survival (117). Segovia et al. reported that host-derived DCregs unpulsed with donor antigens, referred to as autologous DCs, when combined with suboptimal doses of immunosuppression, induced prolonged donor-specific allograft survival through tmem176b-dependent antigen cross-presentation (119).

Moreover, host-derived DCregs were reportedly more efficient in prolonging cardiac allograft survival than donor-derived DCregs (118, 120). From the clinical perspective, host-derived DCregs appear to be more feasible. Host-derived DCregs can be generated in vitro whenever needed while donor-derived DCregs require collecting cells from donors several days prior to transplantation, which is infeasible in cases of deceased organ donation. DCregs using unpulsed, host-derived, immature DCs infused on the day of transplantation decrease the risk of host sensitization against donor antigens (118).

**IN SITU TARGETING OF DCregs**

The infusion of ex vivo-generated DCregs in transplantation to regulate the alloreactive T cell response and to promote transplantation tolerance was evident in experimental models and entered clinical studies (10, 121, 122). However, there are some limitations to the clinical application of this approach, including the risk of host sensitization due to the presence of transferred allogeneic molecules; the risk of rematuration after in vivo fusion, which could promote alloimmunity rather than tolerance; donor-derived DCregs being unsuitable for deceased organ donation; donor-derived DCregs being quickly eliminated by host NK cells; and the decreased ability to migrate to secondary lymphoid organs to present donor antigens. In situ manipulation of DCs is an alternative approach to achieving donor-specific transplantation tolerance. This approach utilizes the in situ delivery of immunomodulatory factors targeting DC to regulate the alloreactive T cell response, thereby avoiding the drawbacks of ex vivo-generated DCregs, and demonstrates the feasibility of tolerance induction.

The clearance of apoptotic cells by DCs is usually immunologically silent and accompanied by TGF-β and IL-10 release (123). Following the phagocytosis of apoptotic cells, DCs begin to exhibit tolerogenic properties. Donor-derived apoptotic cells have been used to deliver both donor antigens and inhibitory signals simultaneously to host DCs to induce antigen-specific allograft tolerance (124). Engulfing of apoptotic DCs converted immature DCs into DCregs that were resistant to LPS-induced maturation and induced the differentiation of Foxp3+ Treg (125). Exosomes are nano-sized membrane-bound extracellular vesicles produced in the endosomal compartment of most eukaryotic cells (126, 127). The phenotype and function of exosomes depend on the origin and state of the cell. DC-derived exosomes may bear MHC molecules, costimulatory molecules, and antigens and function as antigen-presenting nanovesicles (128, 129). Recent research has revealed the role of DC-derived exosomes in allore cognition and transplantation immunity (130). The tolerogenic function of DC-derived exosomes was demonstrated in experimental transplantation models (131, 132). Exosomes from immature, donor-derived DCs induced donor-specific allograft tolerance. Host DCs engulfed these exosomes and presented intact, donor MHC antigens (allo-MHC cross-dressing) and immunomodulatory molecules, such as IL-10, PD-L1, and IDO, in what was considered to be the mechanism underlying microchimerism and tolerance induction (130, 133).

Nanoparticle-based drug delivery systems are a valuable tool in modulating DCs in situ by enabling the direct delivery of encapsulated antigens and immunomodulatory agents via cell-specific targeting in vivo, thus facilitating precise immune regulation to induce transplantation tolerance (134). The poly(lactic-co-glycolic acid) (PLGA) nanoparticles approved by The Food and Drug Administration are the most frequently used nanocarriers. Nanoparticles can also be engineered by coating monoclonal antibodies so that they target specific DC subsets (135, 136). Delivery to DCs can be achieved by targeting DC receptors, including CD11c, CD40, CD205, CD206, CD209, and Fc receptors. The encapsulated agents are protected from enzymatic and chemical degradation, act directly on the DCs, and are more efficient than methods of systemic administration, especially of toxic reagents. Nanoparticle delivery of mycophenolic acid upregulated PD-L1 expression on DCs, prolonged mouse skin allograft survival, and avoided the toxicity of soluble drug delivery (137). Maldonado et al. induced antigen-specific immunological tolerance using polymeric synthetic nanoparticles loaded with antigens and rapamycin, which resulted in suppression of T cell activation and an increase in regulatory cells (138). Clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) is emerging as a powerful tool for engineering the genome in diverse organisms. Zhang et al. encapsulated Cas9 mRNA (mCas9) and a guide RNA targeting CD40 (gCD40) with nanoparticles (139). mCas9/gCD40 was effectively delivered into DCs and disrupted CD40 signaling, significantly protecting grafts from acute rejection-mediated injury and prolonging graft survival. We also developed a novel siRNA delivery system with a poly-d-A extension at the 5′-end of the siRNA sense strand that was stably incorporated into 1,3-β-glucan (schizophyllan, SPG) (140). siRNAs silencing the CD40 gene were delivered into DCs.
through its receptor, Dectin-1, resulting in antigen-specific Treg generation and permanent murine cardiac allograft tolerance. Moreover, nanoparticles have also been used as integrating imaging moieties for monitoring allograft rejection to provide diagnostic and prognostic information as well as for quantifying the treatment efficacy in transplant recipients (134).

Antigen delivery to DCs in vivo using recombinant chimeric antibodies, produced by genetically modifying original monoclonal antibodies and chemically coupling them with peptide antigens, is another promising approach to achieving specific immunomodulation (141, 142). This approach enables the delivery of antigens to DCs under steady-state conditions and the induction of peripheral tolerance (143, 144). Reeves et al. have shown that APC-targeted proinsulin expression converted insulin-specific CD8+ T-cell priming to tolerance in autoimmune-prone NOD mice (145). Ettinger et al. achieved prolonged survival of transgenic mouse skin grafts by utilizing an antibody recognizing the CD205 receptor to deliver the immunodominant domain of type XVII collagen to host DCs without inflammatory stimuli (146).

DCregs IN CLINICAL ORGAN TRANSPLANTATION

In rodent and non-human primate transplantation studies, DCregs exhibited promising potential as a natural, well-tolerated, antigen-specific therapeutic strategy capable of promoting lasting transplantation tolerance. The clinical study of the safety and efficacy of DCregs in transplantations has lagged behind that of autoimmune diseases, including type-1 diabetes, rheumatoid arthritis, and Crohn’s disease, which have reported early safety data (147). Recently, early-phase clinical trials of DCregs in living-donor renal and liver transplantations have begun both in Europe and the US (10, 148).

At the University of Nantes, investigators launched a phase I/II trial of unpulsed autologous DCregs in living-donor renal transplantation (clinicaltrials.gov identifier: NCT0225055). The autologous, monocyte-derived DCregs were generated in a low concentration of GM-CSF and infused into hosts 1 day before transplantation. The hosts also received background immunosuppression with prednisolone, mycophenolate mofetil, and tacrolimus. Recently, the first results and related good manufacturing practice protocols have been published (149, 150). At the University of Pittsburgh, a three-arm, dose-escalation, phase I clinical trial evaluating the safety and feasibility of donor-derived DCreg using a single infusion 1 week prior to living-donor renal transplantation, in combination with mycophenolate mofetil steroid and tacrolimus immunosuppression therapy, is currently underway (NCT0364265).

Given the unique immunological function of the liver, almost half of highly selected liver transplant recipients showed good tolerance even after complete weaning from immunosuppression (151, 152). DCreg-based therapy contributing to antigen-specific tolerance induction may facilitate minimizing immunosuppression and early weaning after liver transplantation. At the University of Pittsburgh, Angus et al. has initiated two phase I/II trials to investigate the safety and efficacy of a single infusion of donor-derived DCreg 1 week before transplantation (NCT03164265) and 1 week before immunosuppression weaning (NCT04208919), respectively, in living donor liver transplant recipients. The donor monocyte-derived DCregs were generated in the presence of IL-10 and Vitamin D3 (153), and the hosts were slowly weaned off immunosuppression after meeting specific criteria.

CONCLUDING REMARKS

Dendritic cells are central instigators and regulators of transplantation immunity and are critical in the balance between allograft rejection and tolerance. Extensive studies focusing on the development, phenotype, and function of DCs have provided important insights into the mechanisms underlying tolerance induction. DCregs comprise a heterogeneous population of immature or semi-mature DCs which expressed low levels of MHC, costimulatory molecules, and altered cytokine production and mediated donor-specific tolerance through alloreactive T cell anergy, T cell deletion, and Treg induction. DCreg-based therapy, by in situ targeting or infusion of ex vivo-generated DCregs represents an emerging approach to preventing rejection and promoting donor-specific tolerance. Further studies are required to explore the translation of DCregs into clinical transplantation to induce tolerance and improve allograft acceptance.

AUTHOR CONTRIBUTIONS

WQ and W-ZG did the literature search and wrote the review. X-KL revised and approved the final version of the review. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported in part by research grants from the National Center for Child Health and Development (30-20), the Ministry of Education, Culture, Sports, Science and Technology of Japan (Nos. 17H04277, 18F17794, 19K18045), and Science and Technology Innovation Talents in Henan Universities (No. 19HASTT003).

REFERENCES

1. Watt KDS, Pedersen RA, Kremers WK, Heinbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant. (2010) 10:1420–7. doi: 10.1111/j.1600-6143.2010.03126.x

2. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. (2003) 349:931–40. doi: 10.1056/NEJMoa021744

3. Valenzuela NM, Reed EF. Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies. J Clin Invest. (2017) 127:2492–504. doi: 10.1172/JCI90597
4. Wood KJ, Goto R. Mechanisms of rejection: current perspectives. *Transplantation*. (2012) 93:1–10. doi: 10.1097/TP.0b013e31823cab44

5. Kwan J, Knechtle SJ. Overcoming chronic rejection can it be? *Transplantation*. (2009) 88:955–61. doi: 10.1097/TP.0b013e3181b96646

6. Long E, Wood KJ. Regulatory T cells in transplantation: transferring mouse studies to the clinic. *Transplantation*. (2009) 88:1050–6. doi: 10.1097/TP.0b013e3181bb7913

7. Roncarolo MG, Gregori S, Bacchetta R, Battaglia M. Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. *Curr Top Microbiol Immunol*. (2014) 380:39–68. doi: 10.1007/978-3-662-43492-3_5

8. Broichhausen C, Riquelme P, Geissler EK, Hutchinson JA. Regulatory macrophages as therapeutic targets and therapeutic agents in solid organ transplantation. *Curr Opin Organ Transplant*. (2012) 17:332–42. doi: 10.1097/MOT.0b013e328355a979

9. Thomson AW, Metes DM, Ezzelarab MB, Raïch-Regué D. Regulatory dendritic cells for human organ transplantation. *Transplant Rev*. (2019) 33:130–6. doi: 10.1016/j.trre.2019.05.001

10. Wood KJ, Bushell A, Hester J. Regulatory immune cells in transplantation. *Nat Rev Immunol*. (2012) 12:417–30. doi: 10.1038/nr2327

11. Papp G, Boros P, Nakken B, Szodoray P, Zeher M. Regulatory immune cells and functions in autoimmunity and transplantation immunology. *Autimmune Rev*. (2017) 16:435–44. doi: 10.1016/j.autrev.2017.03.011

12. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. *Nature*. (1998) 392:245–52. doi: 10.1038/32588

13. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. *Annu Rev Immunol*. (2003) 21:685–711. doi: 10.1146/annurev.immunol.21.120601.141040

14. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. *Annu Rev Immunol*. (2013) 31:563–604. doi: 10.1146/annurev-immunol-020713-155703

15. Eisenbarth SC. Dendritic cell subsets in T cell programming: location dictates function. *Nat Rev Immunol*. (2018) 19:89–103. doi: 10.1038/s41577-018-0088-4

16. Guermounpez P, Valladeau J, Zitvogel L, Théry C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. *Annu Rev Immunol*. (2002) 20:621–67. doi: 10.1146/annurev.immunol.20.100301.064828

17. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. *Proc Natl Acad Sci USA*. (2002) 99:351–8. doi: 10.1073/pnas.231606698

18. Naik SH, Sathe P, Greter M, Hashimoto D, et al. The origin and development of nonlymphoid tissue CD103+ DCs. *J Exp Med*. (2009) 206:3115–30. doi: 10.1073/pnas.20091757

19. Merad M, Manz MG, Karsunky H, Wagers A, Peters W, Charo I, et al. Langerhans cells renew in the skin throughout life under steady-state conditions. *Nat Immunol*. (2002) 3:1135–41. doi: 10.1038/nri852

20. Ginhoux F, Tacke F, Angeli V, Bogunovic M, Loubeau M, Dai X-M, et al. Langerhans cells arise from monocytes in vivo. *Nat Rev Immunol*. (2006) 7:265–73. doi: 10.1038/nri3107

21. Ginhoux F, Liu K, Helft J, Bogunovic M, Greter M, Hashimoto D, et al. The origin and development of nonlymphoid tissue CD103+ DCs. *J Exp Med*. (2009) 206:3115–30. doi: 10.1073/pnas.20091757

22. Merad M, Manz MG, Karsunky H, Wagers A, Peters W, Charo I, et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. *Nat Immunol*. (2012) 13:753–60. doi: 10.1038/ni.2360

23. Coquerelle C, Moser M. DC subsets in positive and negative regulation of immunity. *Immunol Rev*. (2010) 234:317–34. doi: 10.1111/j.1600-0850.2009.00887.x

24. Fogg DK, Siben C, Miled C, Jung S, Auscouterier P, Littman DR, et al. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. *Science*. (2006) 311:83–7. doi: 10.1126/science.1117729

25. Hettinger J, Richards DM, Hansson J, Barra MM, Joschko AC, Krijgsved J, et al. Origin of monocytes and macrophages in a committed progenitor. *Nat Immunol*. (2013) 14:821–30. doi: 10.1038/ni.2638

26. Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. *Nat Rev Immunol*. (2007) 7:19–30. doi: 10.1038/nri1996

27. Mildner A, Yona S, Jung S. A close encounter of the third kind: monocyte-derived cells. *Adv Immunol*. (2013) 120:69–103. doi: 10.1016/B978-0-12-417028-5.00003-X

28. Haniffa M, Collin M, Ginhoux F. Ontogeny and functional specialization of dendritic cells in human and mouse. *Adv Immunol*. (2013) 120:1–49. doi: 10.1016/B978-0-12-417028-5.00001-6

29. Naik SH, Sathe P, Katov HY, Metcalf D, Proietto AI, Dakic A, et al. Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. *Nat Immunol*. (2007) 8:1217–26. doi: 10.1038/nil522

30. Onai N, Obata-Onai A, Schmid MA, Ohteki T, Jarrossay D, Manz MG. Identification of clonogenic common Flt3+ M-CSF-R+ plasmacytoid and...
conventional dendritic cell progenitors in mouse bone marrow. *Nat Immunol.* (2007) 8:1207–16. doi: 10.1038/ni1518

49. Reizis B. Plasmacytoid dendritic cells: development, regulation, and function. *Immunity.* (2019) 50:37–50. doi: 10.1016/j.immuni.2018.12.027

50. Shortman K, Sathe P, Vremec D, Naik S, O’Keefe M. Plasmacytoid dendritic cell development. *Adv Immunol.* (2013) 120:105–26. doi: 10.1016/B978-0-12-417028-5.00004-1

51. Liu K, Victoria GD, Schwickert TA, Guermonprez P, Meredith MM, Yao K, et al. In vivo analysis of dendritic cell development and homeostasis. *Science.* (2009) 324:392–7. doi: 10.1126/science.1170540

52. Liu K, Waskow C, Liu X, Yao K, Hoh J, Nussenzweig M. Origin of dendritic cells in peripheral lymphoid organs of mice. *Nat Immunol.* (2007) 8:578–83. doi: 10.1038/ni1462

53. Schultz C, Gomez Perdigueró E, Chorro L, Szabo-Rogers H, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. *Science.* (2012) 336:86–90. doi: 10.1126/science.1219179

54. Ferrer IR, West HC, Henderson S, Ushakov DS, Sousa P, et al. Analysis of dendritic cell development and homeostasis. *Sci Immunol.* (2016) 7:70. doi: 10.1126/sciimmunol.2007163

55. Steinman RM, Banchereau J. Taking dendritic cells into medicine. *Nat Rev Immunol.* (2002) 63:1164–71. doi: 10.1038/6175

56. Meylan E, Tschopp J. Toll-like receptors and RNA helicases: two sides to parallel ways to trigger antiviral responses. *Mol Cell.* (2006) 22:561–9. doi: 10.1016/j.molcel.2006.05.012

57. Re F, Strominger JL. Heterogeneity of TLR-induced responses in dendritic cells: from innate to adaptive immunity. *Immunobiology.* (2004) 209:191–8. doi: 10.1016/j.imbio.2004.03.005

58. Steinman RM, Banchereau J. Dendritic cells and chemokine production by myeloid and plasmacytoid dendritic cells. *Hum Immunol.* (2002) 63:1164–71. doi: 10.1016/S0198-8859(02)00755-3

59. Colvin BL, Matta BM, Thomson AW. Dendritic cells and chemokine-directed migration in transplantation: where are we headed? *Clin Lab Med.* (2008) 28:375–84. doi: 10.1016/j.cllm.2008.07.003

60. Miller MJ, Wei SH, Parker I, Cahalan MD. Two-photon imaging of lymphocyte motility and antigen response in intact lymph node. *Science.* (2002) 296:1869–73. doi: 10.1126/science.1070051

61. Bousso P, Robey E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. *Nat Immunol.* (2003) 4:579–85. doi: 10.1038/nri298

62. Colvin BL, Matta BM, Thomson AW. Dendritic cells and chemokine-directed migration in transplantation: where are we headed? *Clin Lab Med.* (2008) 28:375–84. doi: 10.1016/j.cllm.2008.07.003

63. Miller MJ, Wei SH, Parker I, Cahalan MD. Two-photon imaging of lymphocyte motility and antigen response in intact lymph node. *Science.* (2002) 296:1869–73. doi: 10.1126/science.1070051

64. Bousso P, Robey E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. *Nat Immunol.* (2003) 4:579–85. doi: 10.1038/nri298

65. Benvenuti F. The dendritic cell synapse: a life dedicated to T cell activation. *Clin Lab Med.* (2002) 22:561–9. doi: 10.1016/S0198-8859(02)00755-3

66. Priyadharshini B, Greiner DL, Brehm MA. T cell activation and chemokine production by myeloid and plasmacytoid dendritic cells. *Immunotherapy.* (2003) 6:1869–73. doi: 10.1126/science.1070051

67. Hasegawa H, Matsumoto T. Mechanisms of tolerance induction by dendritic cells. *Immunotherapy.* (2018) 9:3530. doi: 10.3389/fimmu.2018.03530

68. Lu L, Qian S, Hershberger PA, Rudert WA, Lynch DH, Thomson AW. Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. *J Immunol.* (1997) 158:5676–84.

69. Mellor AL, Baban B, Chandler P, Marshall B, Jhaver K, Hansen A, et al. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. *J Immunol.* (2003) 171:1652–5. doi: 10.4049/jimmunol.171.4.1652

70. Min W-P, Zhou D, Ichim TE, Streban GH, Xie Y, Yang J, et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. *J Immunol.* (2003) 170:1304–12. doi: 10.4049/jimmunol.170.3.1304

71. Sabado RL, Almeida B, Bhardwaj N. Dendritic cell-based immunotherapy. *Cell Res.* (2017) 27:74–95. doi: 10.1038/cr.2016.157

72. Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. *Nat Rev Immunol.* (2004) 4:24–34. doi: 10.1038/nri1256

73. Narango-Gomez M, Raich-Regué D, Ohta C, Grau-López L, Ramo-Tello C, Pujol-Borrell R, et al. Comparative study of clinical grade human tolerogenic dendritic cells. *Transf Med.* (2011) 9:89. doi: 10.1111/j.1697-5876-9.8.9

74. Yamano T, Watanabe S, Hasegawa H, Suzuki T, Abe R, Tahara H, et al. Ex vivo-expanded DCs induce donor-specific central and peripheral tolerance and prolong the acceptance of donor skin grafts. *Blood.* (2011) 117:2640–8. doi: 10.1182/blood-2010-07-293860

75. Eto M, Hackstein H, Kaneko K, Nomoto K, Thomson AW. Promotion of skin graft tolerance across MHC barriers by mobilization of dendritic cells in donor hemopoietic cell infusions. *J Immunol.* (2002) 169:2390–6. doi: 10.4049/jimmunol.169.5.2390

76. Reizis B. Plasmacytoid dendritic cells: development, regulation, and function. *Immunity.* (2019) 50:37–50. doi: 10.1016/j.immuni.2018.12.027

77. Shortman K, Sathe P, Vremec D, Naik S, O’Keefe M. Plasmacytoid dendritic cell development. *Adv Immunol.* (2013) 120:105–26. doi: 10.1016/B978-0-12-417028-5.00004-1

78. Huang X, Yao K, Hoh J, Nussenzweig M. Origin of dendritic cells in peripheral lymphoid organs of mice. *Nat Immunol.* (2007) 8:578–83. doi: 10.1038/ni1462

79. Nussenzweig M. Origin of dendritic cells in peripheral lymphoid organs of mice. *Nat Immunol.* (2007) 8:578–83. doi: 10.1038/ni1462
10. doi: 10.4252/wjsc.v6.i1.1

11. Li Y, Liu M, Yang ST. Dendritic cells derived from pluriptotent stem cells generate antigen-presenting dendritic cells. Sci Rep. (2015) 5:15262. doi: 10.1038/srep15262

12. Fu F, Li Y, Qian S, Lu L, Chambers F, Starzl TE, et al. Costimulatory molecule-deficient dendritic cell progenitors (MHC Class II±, CD80dim, CD86+) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation. (1996) 69:659–65. doi: 10.1097/00007890-199609150-00021

13. Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani G, et al. Use of the inhibitory effect of apoptotic cells on dendritic cells for genetically modify dendritic cells. Am J Transplant. (2017) 178:6318–22. doi: 10.1111/ajt.14811

14. Rastellini C, Lu R, Ricordi C, Starzl TE, Rao AS, Thomson AW. Granulocyte/macrophage colony-stimulating factor-stimulated hepatic dendritic cell progenitors prolong pancreatic islet allograft survival. Transplantation. (1999) 68:1366–70.

15. Davis SJ, Wang Z, Shufesky WJ, Liu Q, Tkacheva OA, Montecalvo A, et al. Endogenous dendritic mediate the effects of intravenously injected therapeutic immunosuppressive dendritic cells in transplantation. Blood. (2010) 116:2694–705. doi: 10.1182/blood-2009-10-251058

16. Wang Z, Divito SJ, Shufesky WJ, Sumpter T, Wang H, Tkacheva OA, et al. Dendritic cell therapies in transplantation revisited: deletion of recipient DCs deters the effect of therapeutic DCs. Am J Transplant. (2012) 12:1398–408. doi: 10.1111/j.1600-6143.2012.04060.x

17. Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW. Rapamycin-treated, allogeneic-pulsed host dendritic cells induce Ag-specific T cell regulation and prolong graft survival. Am J Transplant. (2005) 5:228–36. doi: 10.1111/j.1600-6143.2004.00673.x

18. Pétre H, Trinité B, Martinet B, Cuturi MC. Prolongation of heart allograft survival by immature dendritic cells generated from recipient type bone marrow progenitors. Am J Transplant. (2005) 5:255–67. doi: 10.1111/j.1600-6143.2004.00683.x

19. Segovia M, Pouget F, Savinov A, Balogh T, Gaume L, et al. Autologous dendritic cells prolong allograft survival through Nmnat16b-dependent antigen cross-presentation. Am J Transplant. (2014) 14:1021–31. doi: 10.1111/ajt.12708

20. Li R, Zheng X, Popov I, Zhang X, Wang H, Suzuki M, et al. Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis. J Transl Med. (2009) 7:250. doi: 10.1186/1475-2875-7-250

21. Sordi V, Gianelli G, Buracchi C, Mercalli A, Marchesi F, D’Amico G, et al. Differential effects of immunosuppressive drugs on chemokine receptor CCR7 in human monocyte-derived dendritic cells: selective upregulation by rapamycin. Transplantation. (2006) 82:826–34. doi: 10.1097/01.tp.0000235433.03554.4f

22. Humbert J-M, Halary F. Viral and non-viral methods to genetically modify dendritic cells. Curr Gene Ther. (2012) 12:127–36. doi: 10.2174/156652312800099580

23. Li R, Zheng X, Popov I, Zhang X, Wang H, Suzuki M, et al. Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis. J Transl Med. (2012) 10:19. doi: 10.1186/1475-2875-10-19

24. Li R, Zheng X, Popov I, Zhang X, Wang H, Suzuki M, et al. Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis. J Transl Med. (2012) 10:19. doi: 10.1186/1475-2875-10-19

25. Liang X, Lu L, Chen Z, Vickers T, Zhang H, Fung J, et al. Administration of dendritic cells transduced with antisense oligodeoxynucleotides targeting CD80 or CD86 prolongs allograft survival. Transplantation. (2003) 76:721–729. doi: 10.1097/01.tp.0000076470.3544.49

26. Giannoukakis N, Bonham CA, Qian S, Chen Z, Peng L, Harnaha J, et al. Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxynucleotides. Mol Ther. (2000) 1:430–7. doi: 10.1038/mt.2000.0060

27. Dong Z, Chen Y, Peng Y, Wang F, Yang Z, Huang G, et al. Concurrent CCR7 overexpression and RbE knockdown in immature dendritic cells induces immune tolerance and improves skin-graft survival in a murine model. Cell Physiol Biochem. (2017) 42:455–68. doi: 10.1159/000477593

28. Cai S, Hou J, Fujino M, Zhang Q, Ichimaru N, Takahara S, et al. iPS-derived regulatory dendritic cells inhibit allograft rejection by generating alloantigen-specific regulatory T cells. Stem Cell Reports. (2017) 8:1174–89. doi: 10.1016/j.stemcr.2017.03.020

29. Senju S, Hirata S, Motomura Y, Fukuda D, Matsunaga Y, Fukushima S, et al. Pluripotent stem cells as source of dendritic cells for immune therapy. Int J Hematol. (2010) 91:392–400. doi: 10.1111/j.1742-481X.2009.02117.x

30. Zeng J, Wu C, Wang S. Antigenically modified human pluripotent stem cells generate antigen-presenting dendritic cells. Sci Rep. (2015) 5:15262. doi: 10.1038/srep15262

31. Fu F, Li Y, Qian S, Lu L, Chambers F, Starzl TE, et al. Costimulatory molecule-deficient dendritic cell progenitors (MHC Class II±, CD80dim, CD86+) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation. (1996) 62:659–65. doi: 10.1097/00007890-199609150-00021

32. Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani G, et al. Use of the inhibitory effect of apoptotic cells on dendritic cells for genetically modify dendritic cells. Am J Transplant. (2017) 178:6318–22. doi: 10.1111/ajt.14811

33. Sordi V, Gianelli G, Buracchi C, Mercalli A, Marchesi F, D’Amico G, et al. Differential effects of immunosuppressive drugs on chemokine receptor CCR7 in human monocyte-derived dendritic cells: selective upregulation by rapamycin. Transplantation. (2006) 82:826–34. doi: 10.1097/01.tp.0000235433.03554.4f

34. Humbert J-M, Halary F. Viral and non-viral methods to genetically modify dendritic cells. Curr Gene Ther. (2012) 12:127–36. doi: 10.2174/156652312800099580

35. Li R, Zheng X, Popov I, Zhang X, Wang H, Suzuki M, et al. Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis. J Transl Med. (2012) 10:19. doi: 10.1186/1479-5876-10-19

36. Liang X, Lu L, Chen Z, Vickers T, Zhang H, Fung J, et al. Administration of dendritic cells transduced with antisense oligodeoxynucleotides targeting CD80 or CD86 prolongs allograft survival. Transplantation. (2003) 76:721–729. doi: 10.1097/01.tp.0000076470.3544.49

37. Giannoukakis N, Bonham CA, Qian S, Chen Z, Peng L, Harnaha J, et al. Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxynucleotides. Mol Ther. (2000) 1:430–7. doi: 10.1038/mt.2000.0060

38. Dong Z, Chen Y, Peng Y, Wang F, Yang Z, Huang G, et al. Concurrent CCR7 overexpression and RbE knockdown in immature dendritic cells induces
In vivo

Iberg CA, Hawiger D. Advancing immunomodulation by extracellular vesicles. Nat Immunol. (2002) 3:1156–62. doi: 10.1038/nij854

André F, Chaput N, Schartz NEC, Flament C, Aubert N, Bernard J, et al. Exosomes as potent cell-free peptide-based vaccine. J. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol. (2004) 172:2126–36. doi: 10.4049/jimmunol.172.2.2126

Gonzalez-Nolasco B, Wang M, Pruneville A, Benichou G. Emerging role of exosomes in allorecognition and allograft rejection. Curr Opin Organ Transplant. (2018) 23:22–7. doi: 10.1097/MOT.0000000000000489

Ma B, Yang J-Y, Song W, Zhang R, Zhang Z, Ji H, et al. Combining exosomes derived from immature DCs with donor antigen-specific Treg cells induces tolerance in a rat liver allograft model. Sci Rep. (2016) 6:32971. doi: 10.1038/srep32971

Pêche H, Renaudin K, Beriou G, Merieau E, Amigorena S, Cuturi MC. Induction of tolerance by exosomes and short-term immunosuppression in a fully MHC-mismatched rat cardiac allograft model. Am J Transplant. (2006) 6:1541–50. doi: 10.1111/j.1600-6143.2006.01344.x

Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. (2014) 14:195–208. doi: 10.1038/nri3622

Ochando J, Braza MS. Nanoparticle-based modulation and monitoring of antigen-presenting cells in organ transplantation. Front Immunol. (2017) 8:1888. doi: 10.3389/fimmu.2017.01888

Etzerodt A, Maniecki MB, Graversen JH, Møller HJ, Torchilin VP, Moestrup SK. Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163. J Control Release. (2012) 160:72–80. doi: 10.1016/j.jconrel.2012.01.034

Bahmani B, Uehara M, Jiang L, Ordikhani F, Banouni N, Ichimura T, et al. Targeted delivery of immune therapeutics to lymph nodes prolongs cardiac allograft survival. J Clin Invest. (2018) 128:4770–86. doi: 10.1172/JCI120923

Shirali AC, Wu D, Wus K, Ests E, Stout-Delgado HW, Fahmy TM, et al. Nanoparticle delivery of mycophenolic acid upregulates PD-L1 on dendritic cells to prolong murine allograft survival. J Exp Med. (2011) 217:119302. doi: 10.1084/jem.201103725.x

Maldonado RA, LaMothe RA, Ferrari JD, Zhang AH, Rossi RJ, Kolte PN, et al. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc Natl Acad Sci USA. (2015) 112:E156–65. doi: 10.1073/pnas.140866111

Zhang Y, Shen S, Zhao G, Xu CF, Zhang HB, Luo YL, et al. In situ repurposing of dendritic cells with CRISPR/Cas9-based nanomedicine to induce transplant tolerance. Biomaterials. (2019) 217:119302. doi: 10.1016/j.biomaterials.2019.119302

Zhang Q, Ichimura N, Higuchi S, Cai S, Hou J, Fujino M, et al. Permanent acceptance of mouse cardiac allografts with CD40 siRNA to induce regulatory myeloid cells by use of a novel polysaccharide siRNA delivery system. Gene therapy. (2015) 22:217–26. doi: 10.1038/gt.2014.119

Iberg CA, Hawiger D. Advancing immunomodulation by in vivo antigen delivery to DEC-205 and other cell surface molecules using recombinant chimeric antibodies. Int Immunopharmacol. (2019) 73:575–80. doi: 10.1016/j.intimp.2019.05.037

Iberg CA, Jones A, Hawiger D. Dendritic cells as inducers of peripheral tolerance. Trends Immunol. (2017) 38:793–804. doi: 10.1016/j.it.2017.07.007

Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. (2001) 194:769–79. doi: 10.1084/jem.194.6.769

Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med. (2002) 196:1627–38. doi: 10.1084/jem.20021598

Reeves PL, Rudraraju R, Wong FS, Hamilton-Williams EE, Steptoe RJ. Antigen presenting cell-targeted proinsulin expression converts insulin-specific CD8+ T-cell priming to tolerance in autoimmune-prone NOD mice. Eur J Immunol. (2017) 47:1550–61. doi: 10.1002/eji.201747089

Ettinger M, Gratz IK, Gruber C, Hauser-Kronberger C, Johnson TS, Mahnke K, et al. Targeting of the hNC16A collagen domain to dendritic cells induces tolerance to human type XVII collagen. Exp Dermatol. (2012) 21:395–8. doi: 10.1111/j.1600-0625.2012.01474.x

Ten Brinke A, Hilkens CMU, Cools N, Geissler EK, Hutchinson JA, Lombardi G, et al. Clinical use of tolerogenic dendritic cell-harmonization approach in European collaborative effort. Mediators Inflamm. (2015) 2015:471719. doi: 10.1155/2015/471719

Ochando J, Ordikhani F, Jordan S, Boros P, Thomson AW. Tolerogenic dendritic cells in organ transplantation. Transpl Int. (2020) 33:113–7. doi: 10.1111/tri.13504

Bouchez-Delbos L, Even A, Varey E, Saiagh S, Bercegays G, Braudeau C, et al. Preclinical assessment of autologous tolerogenic dendritic cells from end-stage renal disease patients. Transplantation. (2020). doi: 10.1097/TP.0000000000003315. [Epub ahead of print].

Sawitzki B, Harden PN, Reinke P, Moreau A, Hutchinson JA, Game DS, et al. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet. (2020) 395:1627–39. doi: 10.1016/S0140-6736(20)30167-7

Feng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA. (2012) 307:263–39. doi: 10.1001/jama.2011.2014

Benitez C, Londoño MC, Miquel R, Manzia TM, Abraldes JG, Lozano JJ, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology. (2013) 58:1824–35. doi: 10.1002/hep.24264

 Zahorchak AF, Macedo C, Hamm DE, Butterfield LH, Metes DM, Thomson AW. High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. Cell Immunol. (2018) 323:9–18. doi: 10.1016/j.cellimm.2017.08.008

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Que, Guo and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.